Croda to showcase ProSilic drug delivery technology

New technology will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

Croda will be using CPhI as the launch platform to introduce the novel drug delivery technology ProSilic to the market.

Croda has agreed an exciting strategic partnership with SiSaf, a pioneering UK-based biopharmaceutical company. The arrangement involves the use and development of SiSaf’s patented bio-courier, ProSilic. ProSilic gives Croda’s customers access to the next generation of targeted and controlled drug delivery, which can be tailored to meet their specific needs, whilst offering exceptional safety and versatility. This new technology will be featured at Croda’s stand and SiSaf’s experts will be present for in-depth discussions.

For their Super Refined range of highly purified excipients Croda will present new data evidencing multiple benefits for successful drug formulation. Super Refined excipients have been designed to address various development challenges for multiple administration routes including parenteral, ophthalmic, oral and topical. Extensive study results prove their contribution to maximise the performance of APIs.

On-stand live demonstrations will show the characteristics of Super Refined excipients in practice.